Page last updated: 2024-11-05

3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole and Bladder Cancer

3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole has been researched along with Bladder Cancer in 1 studies

3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole: antineoplastic; activates platelet guanylate cyclase; a radiosensitizing agent and guanylate cyclase activator; structure in first source
lificiguat : A member of the class of indazoles that is 1H-indazole which is substituted by a benzyl group at position 1 and a 5-(hydroxymethyl)-2-furyl group at position 3. It is an activator of soluble guanylate cyclase and inhibits platelet aggregation.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Li, Y1
Zhao, X1
Tang, H1
Zhong, Z1
Zhang, L1
Xu, R1
Li, S1
Wang, Y1

Other Studies

1 other study available for 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole and Bladder Cancer

ArticleYear
Effects of YC-1 on hypoxia-inducible factor 1 alpha in hypoxic human bladder transitional carcinoma cell line T24 cells.
    Urologia internationalis, 2012, Volume: 88, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Transitional Cell; Cell Hypoxia; Cel

2012